New modeling from Boehringer Ingelheim's FIBRONEER™ Phase III trials suggests that nerandomilast, an oral PDE4B inhibitor, could significantly extend median survival in adults with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). The model predicts up to a 5.4-year survival increase in IPF and 3.3 years in PPF compared to no therapy, with additional benefits when combined with standard treatment. These findings, presented at ATS and EULAR 2026, highlight nerandomilast's potential to improve long-term outcomes by slowing lung function decline and reducing mortality risk. Further real-world data and trial extensions will clarify its long-term impact.
Biogen is under investigation by Pomerantz LLP for potential securities fraud following the announcement that its Alzheimer's drug trial missed the primary dose-response endpoint, despite being described as "compelling." The news caused Biogen's stoc...
Biogen has agreed to acquire RayThera Inc. for up to $1 billion, including upfront and milestone payments. This acquisition adds multiple anti-inflammatory drug candidates to Biogen's immunology portfolio, with the lead asset expected to enter Phase ...
Pomerantz LLP is investigating Biogen Inc. for potential securities fraud following the company's announcement that its Phase 2 trial for an Alzheimer's drug, diranersen, missed its primary endpoint despite being described as "compelling." The news c...
